(Q34619876)

3 August 2017

1 reference

title

Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. (English)

1 reference

3 August 2017

1 reference

1

John R Mascola

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 May 2002

1 reference

3 August 2017

1 reference

3 August 2017

volume

20

1 reference

3 August 2017

issue

15

1 reference

3 August 2017

page(s)

1922-1925

1 reference

Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900068-3

7 January 2021

Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900068-3

7 January 2021

Prevention of HIV infection by passive immunization with HIVIG or CD4-IgG

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900068-3

7 January 2021

Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900068-3

7 January 2021

Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900068-3

7 January 2021

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900068-3

7 January 2021

Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900068-3

7 January 2021

Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900068-3

7 January 2021

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900068-3

7 January 2021

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900068-3

7 January 2021

Progesterone implants enhance SIV vaginal transmission and early virus load

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900068-3

7 January 2021

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900068-3

7 January 2021

Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900068-3

7 January 2021

IgG surfaces as an important component in mucosal protection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900068-3

7 January 2021

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900068-3

7 January 2021

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900068-3

7 January 2021

10.1016/S0264-410X(02)00068-3

Identifiers

DOI

1 reference

3 August 2017

1 reference